Satsuma Pharmaceuticals (STSA) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Satsuma Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" STSA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in STSA, but not buy additional shares or sell existing shares.
View STSA analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 1 year price objectives for Satsuma Pharmaceuticals' shares. Their STSA share price forecasts range from $2.00 to $15.00. On average, they anticipate the company's share price to reach $7.40 in the next year. This suggests a possible upside of 598.1% from the stock's current price.
View analysts price targets for STSA or view top-rated stocks among Wall Street analysts.

Satsuma Pharmaceuticals' stock was trading at $0.90 on January 1st, 2023. Since then, STSA shares have increased by 17.8% and is now trading at $1.06.
View the best growth stocks for 2023 here.

Satsuma Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 130,100 shares, a drop of 58.0% from the April 30th total of 310,100 shares. Based on an average daily volume of 1,020,000 shares, the short-interest ratio is presently 0.1 days. Currently, 0.5% of the company's shares are short sold.
View Satsuma Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our STSA earnings forecast.

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) posted its earnings results on Tuesday, March, 28th. The financial services provider reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.32.

Based on aggregate information from My MarketBeat watchlists, some companies that other Satsuma Pharmaceuticals investors own include Verrica Pharmaceuticals (VRCA), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Dynavax Technologies (DVAX), Homology Medicines (FIXX), Gilead Sciences (GILD), Novan (NOVN), Pfizer (PFE) and Akebia Therapeutics (AKBA).

(STSA) raised $75 million in an IPO on Friday, September 13th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore served as the underwriters for the IPO.

Satsuma Pharmaceuticals trades on the NASDAQ under the ticker symbol "STSA."

Satsuma Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Two Sigma Advisers LP (0.83%), Renaissance Technologies LLC (0.50%), FNY Investment Advisers LLC (0.14%) and Bank of America Corp DE (0.11%). Insiders that own company stock include Braden Michael Leonard, Commodore Capital Lp and Thomas P O'neil.
View institutional ownership trends.

Shares of STSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STSA stock can currently be purchased for approximately $1.06.

Satsuma Pharmaceuticals (NASDAQ:STSA) has a market capitalization of $35.14 million. The financial services provider earns $-70,060,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis.

Satsuma Pharmaceuticals' mailing address is 400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO CA, 64080. The official website for the company is www.satsumarx.com. The financial services provider can be reached via phone at 650-410-3200 or via email at cdavis@lifesciadvisors.com.